150
Participants
Start Date
January 30, 2014
Primary Completion Date
May 26, 2016
Study Completion Date
May 26, 2016
Non-Biologic DMARDs
Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
Tocilizumab
Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
Methotrexate
Methotrexate will be administered per investigator's discretion.
ZGT Almelo; Reumatologie, Almelo
Jan Van Breemen Instituut, Amsterdam
Gelre Ziekenhuizen; Reumatologie, Apeldoorn
Amphia ziekenhuis, locatie langendijk, Breda
Albert Schweitzer Ziekenhuis ; Dordwijk, Dordrecht
Universitair Medisch Centrum Groningen; Department of Rheumatology, Groningen
Martini Ziekenhuis, Groningen
Kennemer Gasthuis, Haarlem
Atrium Medisch Centrum, Heerlen
Spaarne Ziekenhuis; Inwendige Geneeskunde, Hoofddorp
Medisch Centrum Leeuwarden; Reumatology, Leeuwarden
Academisch Ziekenhuis Leiden; Dept of Rheumatology, Leiden
Maastricht University Medical Centre; Rheumatology, Maastricht
Erasmus Medisch Centrum; Reumatologie, Rotterdam
Maasstadziekenhuis; Reumatologie, Rotterdam
Vlietland Hospital, Schiedam
Antonius Ziekenhuis Sneek; Department of Rheumatology, Sneek
Leyenburg Ziekenhuis; Internal Medecine, The Hague
St. Bronovo-Nebo, The Hague
University Medical Centre Utrecht; Reumatologie en Klinische Immunologie, Utrecht
Hoffmann-La Roche
INDUSTRY